Senti Biosciences Holdings (SNTI) Common Equity (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Common Equity of $5.6 million for Q4 2025, down 78.21% year-over-year from $25.6 million in Q4 2024, and down 31.18% quarter-over-quarter from $8.1 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Common Equity (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Common Equity history runs 5 years deep, the most recent figure standing at $5.6 million for Q4 2025.
- In Q4 2025, Common Equity fell 78.21% year-over-year to $5.6 million; the TTM figure through Dec 2025 stood at $5.6 million (down 78.21% YoY), while the FY2025 annual figure was $5.6 million, down 78.21% from the prior year.
- Common Equity for Q4 2025 stood at $5.6 million, down from $8.1 million in the prior quarter.
- The five-year high for Common Equity was $154.3 million in Q2 2022, with the low at -$121.8 million in Q1 2022.
- The 5-year median for Common Equity is $31.8 million (2024), against an average of $24.8 million.
- The sharpest annual moves came in 2022 and 2024: Common Equity soared 270.2% in 2022, then plunged 80.72% in 2024.
- Senti Biosciences Holdings' Common Equity stood at -$111.5 million in 2021, then surged by 214.18% to $127.3 million in 2022, then sank by 47.42% to $66.9 million in 2023, then plunged by 61.67% to $25.6 million in 2024, then tumbled by 78.21% to $5.6 million in 2025.
- Business Quant data shows SNTI's Common Equity at $5.6 million in Q4 2025, $8.1 million in Q3 2025, and $24.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Senti Biosciences Holdings | 13.66 Mn | 13.66 Mn | - | -3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.59 Mn |
| Sep 30, 2025 | 8.12 Mn |
| Jun 30, 2025 | 24.65 Mn |
| Mar 31, 2025 | 37.86 Mn |
| Dec 31, 2024 | 25.65 Mn |
| Sep 30, 2024 | 15.99 Mn |
| Jun 30, 2024 | 44.15 Mn |
| Mar 31, 2024 | 56.09 Mn |
| Dec 31, 2023 | 66.91 Mn |
| Sep 30, 2023 | 82.94 Mn |
| Jun 30, 2023 | 97.42 Mn |
| Mar 31, 2023 | 112.34 Mn |
| Dec 31, 2022 | 127.26 Mn |
| Sep 30, 2022 | 140.34 Mn |
| Jun 30, 2022 | 154.27 Mn |
| Mar 31, 2022 | -121.81 Mn |
| Dec 31, 2021 | -111.46 Mn |
| Sep 30, 2021 | -101.37 Mn |
| Jun 30, 2021 | -90.64 Mn |
| Mar 31, 2021 | -79.24 Mn |